UNDER DILIP SHANGHVI, Sun Pharmaceutical Industries Limited, India's largest pharma company, is building additional engines of growth with an eye on the future, especially the specialty business, even as it simultaneously focusses on making the organisation more efficient and profitmaking. The 67-year-old Managing Director of Sun Pharma, in a rare interview and an exclusive one with BT, talks about his vision for the company, the strategy for success, new targets and the way forward. Edited excerpts:
What is your vision for the company and where is it headed?
I don't have the ability to predict the long-term future because there are a large number of variables. However, our focus has always been that each of our businesses should focus on improving its performance over what we did last year. If I look at our major businesses-India, global specialty, and generics businesses in the US and Europe, emerging markets and Japan-I'm expecting each of these businesses to do better than last year. It's only because we keep on improving consistently year after year and we continue to grow faster than the industry. At the same time, we also make research and development (R&D) investments in such a way that some of them produce short-term returns and some produce mid-term returns. And when longterm returns start, it is a step change in terms of the company's growth. We've been making large investments in the specialty business over the past five years, and we are at a position where it will start contributing to the profitability and future growth of the company in a much more meaningful way.
Sun Pharma has recently launched several new products, including specialty drugs. How does the company plan to differentiate itself in these competitive markets, and what are some of the key growth drivers for these products?
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Pension Scheme - Safety Net
The move to introduce the UPS has evoked mixed reactions. Analysts believe its funding will have limited impact on the fiscal math
The Reit Choice?
Real Estate Investment Trusts (Reits) Are Gaining Traction As Interest Rates Stabilise. But Returns Could Be Affected By Adverse Economic Conditions And Market Volatility
CORPORATE - Calling to Account
The sudden exit of Byju's auditor BDO marks the latest in a long series of setbacks for the edtech firm
EMPLOYMENT: Skills Push
The skill development ministry plans to partner with the UGC to improve the employability of undergraduates
Building on a Vision
L&T'S CHAIRMAN EMERITUS A. M. NAIK HAS BUILT A MAMMOTH ENTERPRISE THAT IS BUILDING A NEW INDIA, FROM ITS METRO RAIL SYSTEMS TO THE RAM TEMPLE
"KYS more important than KYC"
Vijay Kedia is a renowned equity investor; the value of his listed portfolio stands at around ₹1,750 crore
ROXX STAR
THE THAR ROXX COMBINES LUXURY WITH PERFORMANCE TO MAKE A STRONG STATEMENT IN THE MID-SIZE SUV SEGMENT
HIT THE GROUND RUNNING
Smartwatches have become indispensable tools for runners, offering real-time insights into pace, distance, heart rate, and more. Here are a few you can consider
TURNING THE TABLES
INDIA'S FURNITURE MARKET IS POISED FOR A GLOBAL TAKE-OFF. ALREADY, A HOST OF GLOBAL BRANDS HAVE MADE THE COUNTRY THEIR HOME, BUT INDIAN COMPANIES ARE NOT TOO FAR BEHIND
THE EVOLUTION OF ATHERA
IDENTIFYING OPPORTUNITIES IN ADVANCE HAS STOOD THIS BENGALURU-BASED VC FUND IN GOOD STEAD. NOW, WITH A HEIGHTENED FOCUS ON TECHNOLOGY, IT WANTS TO SUSTAIN THE SUCCESS